Gynecological Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Adults
Launched by UNIVERSITY HOSPITAL, BORDEAUX · Jun 24, 2025
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study is looking at how a specific treatment called allogeneic hematopoietic stem cell transplantation (a type of bone marrow transplant) affects women's reproductive health after being treated for acute leukemia, a type of blood cancer. The researchers want to understand how common problems like early menopause, vaginal issues related to the transplant, and changes in the cervix are in women who had this treatment as adults. They will review past medical records from one center to see how often these problems occur, how they are followed up, and how they are treated.
Women who might join the study are those who were diagnosed with acute leukemia, had this transplant when they were adults (over 18 years old), are currently between 20 and 45 years old, and had their transplant at least two years ago. Participants need to speak French and be able to understand and read information about the study. Women who had early menopause before their cancer treatment, had a relapse of leukemia after transplant, or are under legal protection cannot take part. If you join, you can expect your medical history related to these gynecological issues to be reviewed, which can help doctors learn more about the effects of this transplant on women’s reproductive health. This study is not yet recruiting participants.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women diagnosed with acute leukemia, who underwent allogeneic hematopoietic stem cell transplantation in adulthood (\>18 years),
- • Aged 20 to 45 at the time of evaluation,
- • At least 2 years post-transplant.
- • French-speaking patients, without comprehension disorders, and literate,
- • No objection to participation.
- Exclusion Criteria:
- • Premature ovarian failure prior to management of haemopathy, post-transplant relapse,
- • Patient under legal protection
About University Hospital, Bordeaux
The University Hospital of Bordeaux is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the institution integrates cutting-edge scientific inquiry with patient care, fostering an environment that encourages collaboration among multidisciplinary teams. With a commitment to improving treatment outcomes and enhancing patient safety, the University Hospital of Bordeaux plays a pivotal role in the development of new therapies and medical technologies, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bordeaux, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported